Safer Human Medicine拟建美国猕猴繁育设施
TechRadar报道称,Safer Human Medicine计划在美国建立一座最终可容纳3万只猴子的繁育设施,种群将在约20年内逐步扩张。公司称,初始种群将由来自亚洲繁育设施的500至1000只猕猴组成,目标是随着AI辅助药物发现带来更多待测候选药物,减少美国实验室对进口实验动物的依赖。该计划面临繁育周期长、动物福利争议以及潜在的法律或监管延误。
随着AI辅助药物发现产生更多可能需要动物测试的治疗方案,该提案直接回应了实验动物资源面临的压力。不过,猕猴繁育需要多年,项目还可能遭遇动物福利方面的挑战、法律行动和监管审查。
- Rapid drug discovery using AI's assistance is adding pressure to an already restricted macaque supply
- A US startup plans to breed 30,000 monkeys over two decades
- China's export ban cut off a major source of American research animals
Artificial intelligence is creating new demands for pharmaceutical research, increasing pressure on all kinds of resources needed to develop and test potential treatments - including animal test subjects.
Macaques, commonly used in medical experiments, have become considerably more expensive, with reported prices rising from approximately $3,000 in 2019 to more than $20,000 today.
Now , Palantir cofounder Joe Lonsdale is reportedly supporting Safer Human Medicine, a startup seeking to establish a large-scale breeding facility in the US.
Rising demand meets restricted monkey supplies
The proposed facility would eventually accommodate 30,000 monkeys, with the company planning to increase its breeding population gradually over approximately 20 years.